Comprehensive Understanding of the Kinetic Behaviors of Main Protease from SARS-CoV-2 and SARS-CoV: New Data and Comparison to Published Parameters

The main protease (M-pro) is a promising drug target for inhibiting the coronavirus due to its conserved properties and lack of homologous genes in humans. However, previous studies on M-pro's kinetic parameters have been confusing, hindering the selection of accurate inhibitors. Therefore, obtaining a clear view of M-pro's kinetic parameters is necessary. In our study, we investigated the kinetic behaviors of M-pro from SARS-CoV-2 and SARS-CoV using both FRET-based cleavage assay and the LC-MS method, respectively. Our findings indicate that the FRET-based cleavage assay could be used for preliminary screening of M-pro inhibitors, while the LC-MS method should be applied to select the effective inhibitors with higher reliability. Furthermore, we constructed the active site mutants (H41A and C145A) and measured the kinetic parameters to gain a deeper understanding of the atomic-level enzyme efficiency reduction compared to the wild type. Overall, our study provides valuable insights for inhibitor screening and design by offering a comprehensive understanding of M-pro's kinetic behaviors.

Automated summary

In this study, we investigated the kinetic behaviors of M-pro from SARS-CoV-2 and SARS-CoV using FRET-based cleavage assay and LC-MS method. Our findings suggest that the FRET-based cleavage assay can be used for preliminary screening of M-pro inhibitors, while the LC-MS method is more reliable for selecting effective inhibitors. Additionally, we constructed active site mutants (H41A and C145A) and measured the kinetic parameters to understand the enzyme efficiency reduction at the atomic level. Overall, our study provides valuable insights for inhibitor screening and design by comprehensively understanding M-pro's kinetic behaviors.